Newsroom

Dr Nicole Schneider-Daum in the laboratory.
News
The lungs have a very complex structure, which makes it difficult to simulate them in the laboratory using human cell line models. As a result, researchers still rely on animal testing in preclinical studies to develop inhaled drugs. A research team led by Dr Nicole Schneider-Daum of the Department of Drug Delivery across Biological Barriers at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has succeeded in establishing a human lung cell line that is suitable for the development of in vitro models. Schneider-Daum's team was awarded the Saarland research prize "Alternatives to animal testing" for this achievement.
15.07.2024
Salmonella under the microscope
News
Bacteria possess unique traits with great potential for benefiting society. However, current genetic engineering methods to harness these advantages are limited to a small fraction of bacterial species. A team led by the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg has now introduced a novel approach that can make many more bacteria amenable to genetic engineering. Their method, called IMPRINT, uses cell-free systems to enhance DNA transformation across various bacterial strains. The findings were published today in the journal Molecular Cell.
26.06.2024
Heavy-ion synchrotron SIS18
News
Researching new vaccines quickly and powerfully for the benefit of mankind — the COVID-19 pandemic rendered clear the need for effective and rapid vaccine development processes. Scientists from the GSI Helmholtzzentrum für Schwerionenforschung in Darmstadt and the Helmholtz Centre for Infection Research (HZI) in Braunschweig investigated an innovative method that has the potential to increase significantly the effectiveness of future vaccine development. This approach uses heavy ion beams to inactivate viruses and thus represents a promising alternative to conventional inactivation methods, which often impair the effectiveness of vaccines. The results were recently published in the scientific journal “Pharmaceutics”.
17.06.2024
Group photo of the Inhoffen Lecture
News
The Friends of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Technische Universität Braunschweig have awarded the 2024 Inhoffen Medal to Prof. Stephan A. Sieber from Technische Universität München for his research into new drugs against multi-resistant bacteria. The award ceremony took place on 13 June 2024 at the House of Science in Braunschweig.
14.06.2024
Electron micrograph of Klebsiella oxytoca
News
The microbiome, the microorganisms that populate our intestines and aid in digestion, weighs around one and a half kilograms. It primarily consists of bacteria and provides protective effects against pathogens entering our digestive system through food, for example. An international team led by Dr Lisa Osbelt-Block and Prof. Till Strowig, both from the Helmholtz Centre for Infection Research (HZI) in Braunschweig, investigated the mechanisms by which the microbiome counters a salmonella infection.
11.06.2024
Thomas Pietschmann at the podcast recording
News
Depending on where you are travelling, different viruses are on the move, some of which can cause life-threatening illnesses. Either through contaminated water or food or through insects that can transmit them when bitten. They can spread all over the world due to climate change, travelling and global transport chains. We have all experienced what this can mean in recent years. What can help: Vaccines and other medicines that help our immune system to fight off these pathogens. Finding them is not so easy. For Professor Thomas Pietschmann, head of the Institute of Experimental Virology at TWINCORE and spokesperson for the "Infection Research" research programme at the HZI, this means: challenge accepted!
31.05.2024

HZI in the media

Quelle: Pressemitteilung

 

HZI-Helmholtz Zentrum für Infektionsforschung ...

04.11.2025
|
LaborPraxis

Forschende des Helmholtz-Zentrums für Infektionsforschung und der Universität Würzburg entwickeln derzeit einen Kaugummi, der Grippeviren

04.11.2025
|
Arbeitsmedizin-Sozialmedizin-Umweltmedizin

... Vakzinologie und angewandte Mikrobiologie am Helmholtz-Zentrum für Infektionsforschung. Die M2-Membranproteinhemmer verhindern ...

02.11.2025
|
Augsburger Allgemeine

... etwas dran ist“, erklärt Biologe Marc Stadler vom Helmholtz-Zentrum für Infektionsforschung gegenüber der Barmer-Krankenkasse. „Es ...

30.10.2025
|
bild der wissenschaft

could be reintroduced at any time. Epidemiologists at the Helmholtz Center for Infection Research (HZI) have now shown that many people do

23.10.2025
|
MSN.com

... eingeschleppt werden könnte. Epidemiolog:innen des Helmholtz-Zentrums für Infektionsforschung (HZI) haben nun gezeigt, dass ...

23.10.2025
|
innovations report

this development, a research team at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), in collaboration with the Swiss

22.10.2025
|
Phys.org

Malaria-Medikamentes ermöglichen könnte. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung in Zusammenarbeit mit ...

22.10.2025
|
Verband Deutscher Biologen e.V.

(Bild: DOI: 10.1021/jacs.5c08354 / Hips / CC BY 4.0) Wissenschaftler am Hips entwickelten eine Plattform zur Produktion von Furanoliden, die effektiv gegen Bakterien und Krebszellen wirken können und vielversprechende Wirkstoffe darstellen.

21.10.2025
|
PROCESS

at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), in partnership with the Helmholtz Centre for Infection Research (HZI

20.10.2025
|
Bioengineer.org

their biological activity. HIPS is a site of the Helmholtz Center for Infection Research (HZI) in collaboration with Saarland University.

20.10.2025
|
Phys.org

... die Abteilung „Experimentelle Immunologie“ am Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig, lehrt als Professor an ...

17.10.2025
|
Deutsches Ärzteblatt

Register now for the HZI-Newsletter